We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TG Therapeutics earned $2.43 per share in Q3, beating estimates and last year's EPS of 2 cents.
Q3 revenues surged 92.8% year over year to $161.7 million on strong Briumvi demand.
The company lifted its 2025 revenue target to about $600 million on strong Briumvi growth.
TG Therapeutics (TGTX - Free Report) reported earnings of $2.43 per share for the third quarter of 2025, which significantly beat the Zacks Consensus Estimate of 24 cents. The company had reported earnings of 2 cents per share in the year-ago quarter.
TGTX’s third-quarter earnings included a non-recurring income tax benefit of around $365 million, driven by the release of deferred tax asset valuation allowance.
Revenues in the third quarter totaled $161.7 million, up almost 92.8% year over year, driven by the strong demand for the company’s sole marketed drug, Briumvi (ublituximab-xiiy). The figure beat the Zacks Consensus Estimate of $152 million.
Briumvi, an anti-CD20 monoclonal antibody, was approved by the FDA for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) in December 2022. The drug is also approved in the European Union, the United Kingdom, Australia and Switzerland.
Shares of TG Therapeutics have increased 12% year to date compared with the industry’s rise of 12.1%.
Image Source: Zacks Investment Research
TGTX's Q3 Earnings in Detail
The top line comprised product sales from Briumvi and license, royalty and other revenues.
Total product revenues were $159.3 million in the third quarter, reflecting an increase of 91.2% year over year. Total product revenues included sales of Briumvi to TGTX’s licensing partner, in ex-U.S. markets, Neuraxpharm, of $6.4 million.
TG Therapeutics has an agreement with Neuraxpharm Pharmaceuticals for the ex-U.S. commercialization of Briumvi, wherein the company is entitled to receive payments upon the achievement of certain commercial milestones and targets.
Briumvi's net product sales in the United States were $152.9 million in the third quarter, up 84% year over year. Sales of the drug increased 10% sequentially.
License, milestone, royalty and other revenues were $2.4 million in the third quarter, compared with $0.6 million reported in the year-ago quarter.
Research and development expenses (excluding non-cash compensation) surged around 107.7% year over year to $35.5 million due to higher manufacturing expenses related to the development of the subcutaneous formulation of Briumvi and increased expenses related to ongoing clinical studies.
Selling, general and administrative expenses (excluding non-cash compensation) totaled $51 million, up almost 53.6% from the year-ago quarter’s level, due to higher commercialization costs for Briumvi as well as other personnel costs.
As of Sept. 30, 2025, TG Therapeutics had cash, cash equivalents and investments worth $178.3 million compared with $278.9 million as of June 30, 2025.
TGTX’s 2025 Guidance Raised
Based on the continued growth in Briumvi revenues, TG Therapeutics raised its full-year revenue guidance for 2025.
The company now expects to record worldwide revenues of approximately $600 million in 2025 compared with the earlier expectation of $585 million.
For full-year 2025, net product sales of Briumvi are expected to be around $585 million in the United States, compared with the earlier projection of $570-$575 million.
Operating expenses (excluding non-cash compensation and cost of goods sold) are expected to be around $300-$320 million for full-year 2025.
TGTX's Recent Pipeline Updates
Several additional studies on Briumvi targeting other autoimmune diseases are currently ongoing.
TG Therapeutics recently commenced patient enrollment in the phase III pivotal program for subcutaneous Briumvi in RMS.
The company has completed patient enrollment in the phase III ENHANCE study evaluating the potential to consolidate the day one and day 15 infusions of intravenous Briumvi into a single 600-mg infusion on day one.
TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T cell therapy, in a phase I study for treating patients with primary progressive multiple sclerosis.
TG Therapeutics, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 70.2%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
In the past 60 days, estimates for Arcutis Biotherapeutics’ loss per share have narrowed from 44 cents to 24 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 9 cents to 41 cents. Year to date, shares of ARQT have rallied 77.7%.
Arcutis Biotherapeutics’ earnings beat estimates in each of the trailing four quarters, the average surprise being 64.80%.
In the past 60 days, estimates for Intellia’s loss per share have narrowed from $4.15 to $4.11 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.12 to $4.07. Year to date, shares of NTLA have gained 12.1%.
Intellia’s earnings beat estimates in each of the trailing four quarters, the average surprise being 6.21%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
Key Takeaways
TG Therapeutics (TGTX - Free Report) reported earnings of $2.43 per share for the third quarter of 2025, which significantly beat the Zacks Consensus Estimate of 24 cents. The company had reported earnings of 2 cents per share in the year-ago quarter.
TGTX’s third-quarter earnings included a non-recurring income tax benefit of around $365 million, driven by the release of deferred tax asset valuation allowance.
Revenues in the third quarter totaled $161.7 million, up almost 92.8% year over year, driven by the strong demand for the company’s sole marketed drug, Briumvi (ublituximab-xiiy). The figure beat the Zacks Consensus Estimate of $152 million.
Briumvi, an anti-CD20 monoclonal antibody, was approved by the FDA for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) in December 2022. The drug is also approved in the European Union, the United Kingdom, Australia and Switzerland.
Shares of TG Therapeutics have increased 12% year to date compared with the industry’s rise of 12.1%.
Image Source: Zacks Investment Research
TGTX's Q3 Earnings in Detail
The top line comprised product sales from Briumvi and license, royalty and other revenues.
Total product revenues were $159.3 million in the third quarter, reflecting an increase of 91.2% year over year. Total product revenues included sales of Briumvi to TGTX’s licensing partner, in ex-U.S. markets, Neuraxpharm, of $6.4 million.
TG Therapeutics has an agreement with Neuraxpharm Pharmaceuticals for the ex-U.S. commercialization of Briumvi, wherein the company is entitled to receive payments upon the achievement of certain commercial milestones and targets.
Briumvi's net product sales in the United States were $152.9 million in the third quarter, up 84% year over year. Sales of the drug increased 10% sequentially.
License, milestone, royalty and other revenues were $2.4 million in the third quarter, compared with $0.6 million reported in the year-ago quarter.
Research and development expenses (excluding non-cash compensation) surged around 107.7% year over year to $35.5 million due to higher manufacturing expenses related to the development of the subcutaneous formulation of Briumvi and increased expenses related to ongoing clinical studies.
Selling, general and administrative expenses (excluding non-cash compensation) totaled $51 million, up almost 53.6% from the year-ago quarter’s level, due to higher commercialization costs for Briumvi as well as other personnel costs.
As of Sept. 30, 2025, TG Therapeutics had cash, cash equivalents and investments worth $178.3 million compared with $278.9 million as of June 30, 2025.
TGTX’s 2025 Guidance Raised
Based on the continued growth in Briumvi revenues, TG Therapeutics raised its full-year revenue guidance for 2025.
The company now expects to record worldwide revenues of approximately $600 million in 2025 compared with the earlier expectation of $585 million.
For full-year 2025, net product sales of Briumvi are expected to be around $585 million in the United States, compared with the earlier projection of $570-$575 million.
Operating expenses (excluding non-cash compensation and cost of goods sold) are expected to be around $300-$320 million for full-year 2025.
TGTX's Recent Pipeline Updates
Several additional studies on Briumvi targeting other autoimmune diseases are currently ongoing.
TG Therapeutics recently commenced patient enrollment in the phase III pivotal program for subcutaneous Briumvi in RMS.
The company has completed patient enrollment in the phase III ENHANCE study evaluating the potential to consolidate the day one and day 15 infusions of intravenous Briumvi into a single 600-mg infusion on day one.
TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T cell therapy, in a phase I study for treating patients with primary progressive multiple sclerosis.
TG Therapeutics, Inc. Price, Consensus and EPS Surprise
TG Therapeutics, Inc. price-consensus-eps-surprise-chart | TG Therapeutics, Inc. Quote
TGTX's Zacks Rank & Stocks to Consider
TG Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) , Arcutis Biotherapeutics (ARQT - Free Report) and Intellia Therapeutics (NTLA - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 70.2%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
In the past 60 days, estimates for Arcutis Biotherapeutics’ loss per share have narrowed from 44 cents to 24 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 9 cents to 41 cents. Year to date, shares of ARQT have rallied 77.7%.
Arcutis Biotherapeutics’ earnings beat estimates in each of the trailing four quarters, the average surprise being 64.80%.
In the past 60 days, estimates for Intellia’s loss per share have narrowed from $4.15 to $4.11 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.12 to $4.07. Year to date, shares of NTLA have gained 12.1%.
Intellia’s earnings beat estimates in each of the trailing four quarters, the average surprise being 6.21%.